HALO

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:HALO

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	21 : 30	PR Newswire (US)	Halozyme to Participate in Upcoming Investor Conferences	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/05/08	05 : 09	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/05/08	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/05/08	05 : 01	PR Newswire (US)	HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/04/26	05 : 45	PR Newswire (US)	Mahesh Krishnan Elected to Halozyme's Board of Directors	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/04/23	21 : 30	PR Newswire (US)	Halozyme to Report First Quarter 2024 Financial and Operating Results	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/03/05	06 : 13	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/29	08 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/29	06 : 07	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/28	07 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/28	07 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/28	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/28	06 : 08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/27	22 : 30	PR Newswire (US)	Halozyme to Participate in Upcoming Investor Conferences	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	08 : 59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	08 : 55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	08 : 53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	08 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	06 : 07	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	06 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/21	06 : 01	PR Newswire (US)	HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/17	07 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/17	07 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/17	07 : 39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/14	06 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/14	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/14	06 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/12	20 : 19	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/02/09	06 : 30	PR Newswire (US)	Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results	NASDAQ:HALO	Halozyme Therapeutics Incorporated
2024/01/30	06 : 15	PR Newswire (US)	Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	NASDAQ:HALO	Halozyme Therapeutics Incorporated